New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Clinical Therapeutics

• Publication date

  2013-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clinthera.2013.06.019PMID 23932550
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway.

  2013cited by this paper
• Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.

  2013cited by this paper
• Pathogenesis of acute coronary syndromes.

  2013cited by this paper
• PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics

  2013cited by this paper
• Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

  2012cited by this paper
• Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia

  2012cited by this paper
• Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.

  2012cited by this paper
• Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia: Results of a Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety as Add-On Therapy in Patients With Coronary Artery Disease

  2012cited by this paper
• PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates.

  2012cited by this paper
• Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.

  2012cited by this paper
• Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study.

  2012cited by this paper
• Multiple functions of microsomal triglyceride transfer protein

  2012cited by this paper
• On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).

  2012cited by this paper
• Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study.

  2012cited by this paper
• Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy

  2012cited by this paper
• Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.

  2012cited by this paper
• Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia: The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterole

  2012cited by this paper
• Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins.

  2012cited by this paper
• Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.

  2012cited by this paper
• Novel therapeutic agents for lowering low density lipoprotein cholesterol.

  2012cited by this paper
• The PCSK9 decade

  2012cited by this paper
• Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.

  2012cited by this paper
• A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo1[S]

  2011cited by this paper
• Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

  2011cited by this paper
• Clinical aspects of PCSK9.

  2011cited by this paper
• Pharmacological Characterization of Diethyl-2-({3-dimethylcarbamoyl-4-[(4′-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetyloxymethyl)-2-phenylmalonate (JTT-130), an Intestine-Specific Inhibitor of Microsomal Triglyceride Transfer Protein

  2011cited by this paper
• Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue

  2011cited by this paper
• Antisense oligonucleotides for the treatment of dyslipidemia.

  2011cited by this paper
• Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia.

  2011cited by this paper
• A Small-Molecule Inhibitor of Enterocytic Microsomal Triglyceride Transfer Protein, SLx-4090: Biochemical, Pharmacodynamic, Pharmacokinetic, and Safety Profile

  2011cited by this paper
• Apolipoprotein B Synthesis Inhibition by Mipomersen Reduces LDL-C When Added to Maximally Tolerated Lipid-Lowering Medication in Patients with Severe Heterozygous Hypercholesterolemia†

  2011cited by this paper
• Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover study.

  2011cited by this paper
• Inhibition of microsomal triglyceride transfer protein improves insulin sensitivity and reduces atherogenic risk in Zucker fatty rats

  2011cited by this paper
• APOLIPOPROTEIN B SYNTHESIS INHIBITION BY MIPOMERSEN REDUCES LOW-DENSITY LIPOPROTEIN CHOLESTEROL WHEN ADDED TO MAXIMALLY TOLERATED LIPID-LOWERING MEDICATION IN PATIENTS WITH SEVERE HETEROZYGOUS HYPERCHOLESTEROLEMIA

  2011cited by this paper
• UvA-DARE ( Digital Academic Repository ) Dyslipidemia , sense , antisense or nonsense ?

  2011cited by this paper
• Novel Domain Interaction Regulates Secretion of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein*

  2011cited by this paper
• Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.

  2010cited by this paper
• High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol

  2010cited by this paper
• PCSK9 as a Therapeutic Target in Atherosclerosis

  2010cited by this paper
• Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy.

  2010cited by this paper
• Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.

  2010cited by this paper
• Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels

  2010cited by this paper
• Adnectins: engineered target-binding protein therapeutics

  2010cited by this paper
• A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo

  2010cited by this paper
• Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

  2010cited by this paper
• RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform.

  2010cited by this paper
• Targeting ApoB as a therapeutic approach for the treatment of dyslipidemia: the potential role of mipomersen

  2010cited by this paper
• A new method for measurement of total plasma PCSK9: clinical applications

  2010cited by this paper
• Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia.

  2010cited by this paper
• PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion.

  2009cited by this paper
• Hepatocyte Nuclear Factor 1α Plays a Critical Role in PCSK9 Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine*

  2009cited by this paper
• Acute coronary syndromes: morbidity, mortality, and pharmacoeconomic burden.

  2009cited by this paper
• Lack of Pharmacokinetic Interaction of Mipomersen Sodium (ISIS 301012), a 2′-—O-Methoxyethyl Modified Antisense Oligonucleotide Targeting Apolipoprotein B-100 Messenger RNA, with Simvastatin and Ezetimibe

  2009cited by this paper
• PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial Hypobetalipoproteinemia

  2009cited by this paper
• Genetic and metabolic determinants of plasma PCSK9 levels.

  2009cited by this paper
• Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells*

  2009cited by this paper
• Abstract: P471 IMPACT OF THE MTP-INHIBITOR AEGR-733 ON THE SINGLE-DOSE PHARMACOKINETICS OF EXTENDED-RELEASE NIACIN

  2009cited by this paper
• A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

  2009cited by this paper
• Plasma PCSK9 levels are significantly modified by statins and fibrates in humans

  2008cited by this paper
• Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population.

  2008cited by this paper
• Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9 Published, JLR Papers in Press, November 21, 2007.

  2008cited by this paper
• Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes

  2008cited by this paper
• Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia

  2008cited by this paper
• PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide.

  2008cited by this paper
• Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

  2008cited by this paper
• Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9*

  2008cited by this paper
• New approaches to target microsomal triglyceride transfer protein

  2008cited by this paper
• Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment.

  2008cited by this paper
• Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol.

  2007cited by this paper
• Impact of the MTP Inhibitor AEGR-733 on Pharmacokinetics of Statins

  2007cited by this paper
• Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia.

  2007cited by this paper
• Impact of high doses of the MTP-Inhibitor, AEGR-733, on the single dose Pharmacokinetics of Atorvastatin and Rosuvastatin

  2007cited by this paper
• Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice Published, JLR Papers in Press, January 22, 2007.

  2007cited by this paper
• ISIS 301012 Gene Therapy for Hypercholesterolemia: Sense, Antisense, or Nonsense?

  2007cited by this paper
• Improving Prediction of Ischemic Cardiovascular Disease in the General Population Using Apolipoprotein B: The Copenhagen City Heart Study

  2007cited by this paper
• Molecular diagnosis of hypobetalipoproteinemia: an ENID review.

  2007cited by this paper
• patient-oriented and epidemiological research Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese

  2007cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

  2007cited by this paper
• The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis

  2007cited by this paper
• Burden of disease: medical and economic impact of acute coronary syndromes.

  2006cited by this paper
• Contemporary management of dyslipidemia in high-risk patients: targets still not met.

  2006cited by this paper
• Potent Reduction of Apolipoprotein B and Low-Density Lipoprotein Cholesterol by Short-Term Administration of an Antisense Inhibitor of Apolipoprotein B

  2006cited by this paper
• Hepatic steatosis and insulin resistance: does etiology make a difference?

  2006cited by this paper
• The Proprotein Convertase (PC) PCSK9 Is Inactivated by Furin and/or PC5/6A

  2006cited by this paper
• Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote.

  2006cited by this paper
• 'Endocrine NAFLD' a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis.

  2006cited by this paper
• A 15-ketosterol is a liver X receptor ligand that suppresses sterol-responsive element binding protein-2 activity1

  2006cited by this paper
• Abstract 340: The C679X Mutation in PCSK9 is Present and Lowers Blood Cholesterol in a Southern African Population

  2006cited by this paper
• Hepatic PCSK9 Expression Is Regulated by Nutritional Status via Insulin and Sterol Regulatory Element-binding Protein 1c*

  2006cited by this paper
• Apolipoprotein-B, low-density lipoprotein cholesterol, and the long-term risk of coronary heart disease in men.

  2006cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

  2005cited by this paper
• Implitapide, a microsomal triglyceride transfer protein inhibitor, reduces progression of atherosclerosis in apolipoprotein E knockout mice fed a Western-type diet: involvement of the inhibition of postprandial triglyceride elevation.

  2005cited by this paper
• Focus Issue: PROVE IT-TIMI 22Can Low-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein With Intensive Statin Therapy: A PROVE IT-TIMI 22 Substudy

  2005cited by this paper
• Pleiotropic effects of statins.

  2005cited by this paper
• Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.

  2005cited by this paper
• Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.

  2005cited by this paper
• JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs

  2005cited by this paper
• Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

  2004cited by this paper
• Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.

  2004cited by this paper
• SREBP transcription factors: master regulators of lipid homeostasis.

  2004cited by this paper

• Pleiotropic Effects of Statins: Focus on Inflammation, Oxidative Stress and Immunomodulation (Part I)

  2026cites this paper
• The Impact of Lipoprotein Apheresis on Changes in Biochemical Enzymes: A Systematic Review and Meta‐Analysis

  2026cites this paper
• Cholesteryl Ester Transfer Protein Inhibitors: State of the Science

  2026cites this paper
• Statins as Modulators of Epithelial to Mesenchymal Transition in Cardiovascular-Kidney-Metabolic Syndrome: a Comprehensive Review of Mechanisms and Therapeutic Implications

  2025cites this paper
• Gut microbiota–cholesterol crosstalk in cardiovascular diseases: mechanisms, metabolites, and therapeutic modulation

  2025cites this paper
• From physiopathology to treatment of familial hypercholesterolemia: Existing and emerging pharmacotherapies.

  2025cites this paper
• The Impact of Lipid Apheresis on Changes of Plasma Ions: A Systematic Review and Meta‐Analysis

  2025cites this paper
• Cutting-edge lipid-lowering pharmacological therapies: Improving lipid control beyond statins.

  2025cites this paper
• Effects of PCSK9 inhibitors on cancer, diabetes, and cardiovascular diseases.

  2025cites this paper
• The effect of vitamin E supplementation on serum low-density lipoprotein oxidization: A systematic review and meta-analysis of clinical trials.

  2025cites this paper
• Gold Nanoparticles in Atherosclerosis: A Dual Approach to Diagnosis and Therapy

  2025cites this paper
• Phytochemicals from medicinal plants as alternative therapeutics for metabolic syndrome: A review of randomized controlled trials

  2025cites this paper
• Post-transcriptional targeting of PCSK9 by microRNAs: From mechanisms to therapeutic potential

  2025cites this paper
• Cardiovascular risk management beyond statins: review of new therapies available in Italy

  2025cites this paper
• Statins and adhesion molecules: a review of a novel pleiotropic property of statins

  2025cites this paper
• An exploration of molecular signaling in drug reprocessing for Oral Squamous Cell Carcinoma.

  2025cites this paper
• Nanozymes: A novel approach to upgrade atherosclerosis treatment.

  2025cites this paper
• Effect of Dietary Approaches to Stop Hypertension (DASH) diet on lipid profile in individuals with overweight/ obesity: A GRADE-assessed systematic review and meta-analysis of clinical trials.

  2025cites this paper
• Angiopoietin-like protein inhibitors: Promising agents for the treatment of familial hypercholesterolemia and atherogenic dyslipidemia.

  2025cites this paper
• Effects of Pioglitazone On Lipoprotein(a): A Meta-analysis

  2025cites this paper
• Beyond cardiovascular health: The pharmacotherapeutic potential of statins in oncology.

  2025cites this paper
• Brief Overview of Statins for Lowering Low-Density Lipid Cholesterol

  2024cites this paper
• Lipidomic profiling in patients with familial hypercholesterolemia: Abnormalities in glycerolipids and oxysterols.

  2024cites this paper
• The Effect of Statin Therapy on Bone Metabolism Markers and Mineral Density: Aa GRADE-Assessed Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials

  2024cites this paper
• The role of natural products as PCSK9 modulators: A review

  2024cites this paper
• Targeting PCSK9 as a key player in lipid metabolism: exploiting the therapeutic and biosensing potential of aptamers

  2024cites this paper
• Regulatory effects of statins on Akt signaling for prevention of cancers.

  2024cites this paper
• Modulating effects of crocin on lipids and lipoproteins: Mechanisms and potential benefits

  2024cites this paper
• Identification and analysis of the molecular targets of statins in colorectal cancer.

  2024cites this paper
• The protective effects of statins in traumatic brain injury

  2024cites this paper
• Effect of statins on arterial wall inflammation as assessed by 18F-FDG PET CT: an updated systematic review and meta-analysis

  2024cites this paper
• Regulatory effects of statins on CCL2/CCR2 axis in cardiovascular diseases: new insight into pleiotropic effects of statins

  2024cites this paper
• Impact of statin therapy on CD40:CD40L signaling: mechanistic insights and therapeutic opportunities

  2024cites this paper
• The role of electrochemical biosensors in monitoring Apolipoprotein B-100 as a diagnostic tool for cardiovascular disease

  2024cites this paper
• Statin Therapy and C-reactive Protein in Patients with Kidney Disease: A Systematic Review and Meta-analysis of Randomized Clinical Trials.

  2024cites this paper
• Statins as a Potential Treatment for Non-Alcoholic Fatty Liver Disease: Target Deconvolution using Protein-protein Interaction Network Analysis.

  2023cites this paper
• Roles of PCSK9 in the pathogenesis of periodontal disease.

  2023cites this paper
• Gender Differences in the Association between Cholesteryl Esters Transfer Protein Polymorphism (rs708272) and Plasma Lipid Levels in Hyperlipidaemic Participants at Hospital Universiti Sains Malaysia

  2023cites this paper
• Purple perilla frutescens extracts containing α-asarone inhibit inflammatory atheroma formation and promote hepatic HDL cholesterol uptake in dyslipidemic apoE-deficient mice

  2023cites this paper
• Lipid-lowering drugs and cancer: an updated perspective

  2023cites this paper
• Atherosclerosis Potential Drug Targets: Current Scenario and Future Perspectives.

  2023cites this paper
• Identification of Potent Small-Molecule PCSK9 Inhibitors Based on Quantitative Structure-Activity Relationship, Pharmacophore Modeling, and Molecular Docking Procedure.

  2023cites this paper
• Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives

  2023cites this paper
• Statins and angiogenesis in non-cardiovascular diseases.

  2022cites this paper
• Evaluation of miRNA-27a/b expression in patients with familial hypercholesterolemia

  2022cites this paper
• The effect of combination therapy with statins and ezetimibe on proinflammatory cytokines: A systematic review and meta-analysis of randomized controlled trials.

  2022cites this paper
• Berberine: Ins and outs of a nature-made PCSK9 inhibitor

  2022cites this paper
• The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition

  2022cites this paper
• The immunogenic potential of PCSK9 peptide vaccine in mice.

  2022cites this paper
• Statin-regulated phagocytosis and efferocytosis in physiological and pathological conditions.

  2022cites this paper
• The Effects of Statin Treatment on Serum Ferritin Levels: A Systematic Review and Meta-Analysis

  2022cites this paper
• Effect of statins on abdominal aortic aneurysm.

  2022cites this paper
• The effect of statin therapy in combination with ezetimibe on circulating C-reactive protein levels: a systematic review and meta-analysis of randomized controlled trials

  2022cites this paper
• The Effect of Bariatric Surgery on Circulating Levels of Lipoprotein (a): A Meta-analysis

  2022cites this paper
• The Effects of Statin Therapy on Oxidized LDL and Its Antibodies: A Systematic Review and Meta-Analysis

  2022cites this paper
• Therapeutic effects of statins on osteoarthritis: A review

  2022cites this paper
• Pleotropic properties of statins via angiogenesis modulation in cardiovascular disease.

  2022cites this paper
• The effect of PCSK9 immunization on the hepatic level of microRNAs associated with the PCSK9/LDLR pathway

  2022influential citation
• Role of statins in regulating molecular pathways following traumatic brain injury: A system pharmacology study.

  2022cites this paper
• Regulatory Effects of Statins on SIRT1 and Other Sirtuins in Cardiovascular Diseases

  2022cites this paper
• Effects of statins on specialized pro-resolving mediators: An additional pathway leading to resolution of inflammation.

  2022cites this paper
• Cellular and Molecular Aspects of Managing Familial Hypercholesterolemia: Recent and Emerging Therapeutic Approaches.

  2022cites this paper
• Antioxidant Effects of Statins by Modulating Nrf2 and Nrf2/HO-1 Signaling in Different Diseases

  2022cites this paper
• Effect of statins on the plasma/serum levels of inflammatory markers in patients with cardiovascular disease; a systematic review and meta-analysis of randomized clinical trials

  2022cites this paper
• Effect of Statins on Serum level of hs-CRP and CRP in Patients with Cardiovascular Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2022cites this paper
• Statins block mammalian target of rapamycin pathway: a possible novel therapeutic strategy for inflammatory, malignant and neurodegenerative diseases

  2022cites this paper
• The effects of statins on the function and differentiation of blood cells

  2022cites this paper
• How statin drugs affect exosomes?

  2022cites this paper
• Effect of statins on the blood lipid profile in patients with different cardiovascular diseases: a systematic review with meta-analysis of randomized clinical trials .

  2022cites this paper
• In silico and in vitro analysis of microRNAs with therapeutic potential in atherosclerosis

  2022cites this paper
• PCSK9 inhibition-based therapeutic approaches: an immunotherapy perspective.

  2021cites this paper
• The effect of temperature on the stability of PCSK-9 monoclonal antibody: an experimental study

  2021influential citation
• Update on Statin Treatment in Patients with Neuropsychiatric Disorders

  2021cites this paper
• Lipoprotein(a) Where Do We Stand? From the Physiopathology to Innovative Terapy

  2021cites this paper
• Variants Near CETP, MTTP and BUD13-ZPR1-APOA5 may be Nominally Associated with Poor Statin Response Among Filipinos

  2021cites this paper
• Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis

  2021cites this paper
• Harnessing Therapeutic Potentials of Statins Using Nanofibrous Carriers

  2021cites this paper
• The cardioprotective actions of statins in targeting mitochondrial dysfunction associated with myocardial ischaemia-reperfusion injury.

  2021cites this paper
• Serum lipoprotein(a) and risk of periprocedural myocardial injury in patients undergoing percutaneous coronary intervention

  2020cites this paper
• Butein Synergizes with Statin to Upregulate Low-Density Lipoprotein Receptor Through HNF1α-Mediated PCSK9 Inhibition in HepG2 Cells

  2020cites this paper
• LDL-Cholesterol-Lowering Therapy.

  2020cites this paper
• Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule

  2020cites this paper
• Physicochemical characterization and pharmacokinetic evaluation of rosuvastatin calcium incorporated solid lipid nanoparticles.

  2020cites this paper
• Effects of vitamin D supplementation on serum lipid profile in women with polycystic ovary syndrome

  2020cites this paper
• Seed) Effects on Plasma Lipid Concentrations in Humans: a Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials

  2020cites this paper
• Effects of immunization against PCSK9 in an experimental model of breast cancer

  2019cites this paper
• Amino Acids and Their Metabolism in Atherosclerosis

  2019cites this paper
• Safety and efficacy of alirocumab: A meta analysis of 12 randomized controlled trials

  2019cites this paper
• Current Drugs and Nutraceuticals for the Treatment of Patients with Dyslipidemias.

  2019cites this paper
• American Heart Association’s Cholesterol CarePlan as a Smartphone-Delivered Web App for Patients Prescribed Cholesterol-Lowering Medication: Protocol for an Observational Feasibility Study

  2019cites this paper
• Letter: Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome (Diabetes Metab J 2018;42:207-14)

  2018cites this paper
• The impact of argan oil on plasma lipids in humans: Systematic review and meta‐analysis of randomized controlled trials

  2018cites this paper
• Lipoprotein(a): A missing culprit in the management of athero‐thrombosis?

  2018cites this paper
• Neurocognitive performance after PCSK9 inhibitor therapy: Current state of the evidence

  2018cites this paper
• HDL functionality in familial hypercholesterolemia: effects of treatment modalities and pharmacological interventions.

  2018cites this paper
• PCSK9 and infection: A potentially useful or dangerous association?

  2018cites this paper
• Monocyte‐to‐HDL‐cholesterol ratio as a prognostic marker in cardiovascular diseases

  2018cites this paper
• Evaluation of serum cathepsin D concentrations in coronary artery disease

  2018cites this paper
• Familial hypercholesterolemia treatments: Guidelines and new therapies.

  2018cites this paper
• OBSOLETE: Familial Hypercholesterolemia

  2018cites this paper